Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines
The University of Navarra Hospital (Spain) has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself - and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours. The new therapy is administered to participating patients combined with the standard, first-line treatment involving surgical extirpation of the tumour followed by radiotherapy and chemotherapy treatment with temozolomide. The Hospital is currently the only centre in Spain undertaking a study of this nature, and for which it has recently received authorisation from the Medication Agency of the Spanish Health Ministry. It is planned to involve a sample of 37 patients for the research.